GlassScriptPhysician profile
Stephen Robert Dominey
NPI 1831646041
$2,830.84
in general payments reported to CMS, 2019-2025
21 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $761 · 2023: $681 · 2024: $268 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242 · Education: $72.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.18 |
| Education | $72.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $381.77 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $356.41 | 2021-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $266.24 | 2021-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $213.52 | 2021-2025 | Jynarque |
| Amgen INC. | $200.98 | 2021-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $196.37 | 2022-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $191.65 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $185.85 | 2021-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $134.33 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $113.02 | 2021-2023 | Velphoro, Korsuva |
| Horizon Therapeutics Plc | $95.61 | 2021-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $95.54 | 2021-2024 | Ultomiris |
| Travere Therapeutics, INC. | $66.47 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $65.03 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $53.14 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.70 | 2022 | |
| Merck Sharp & Dohme LLC | $50.52 | 2024-2025 | Prevymis |
| Akebia Therapeutics INC | $41.91 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $33.77 | 2021-2023 | |
| Daiichi Sankyo INC. | $18.74 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.27 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dominey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.